Clene Inc.

NASDAQ:CLNN

Biotechnology

Healthcare
$3.66 +1.35%

+$0.08 today

Market cap
$52.70M
Beta
0.92
P/E (TTM)
-2.1
EPS (TTM)
-$2.88
52W Low $3.25High $13.50

Volume 0.12M

Average 0.50M

CLNN Debt Repayment

Cash used to repay borrowings during the period.

Clene Inc.NASDAQ: CLNN

Debt Repayment · Q1 FY2026 · quarter ended Mar 2026

Debt repayment turns negative

Q1 FY2026 debt repayment was -$90K, compared with $0 a year earlier. Trailing-twelve-month debt repayment was -$90K. Over 3 fiscal years it compounded at -41.4% a year.

Context

  • Debt repayment amounted to 558.0% of revenue in FY2025, down 2628.0 pp from a year earlier.
  • Debt repayment increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly debt repayment holds near -$90K or moves back toward the trailing-twelve-month quarterly average of -$22.5K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$90K-130.6% QoQ
Last fiscal yearDec 2025
$1.12M+110.2% YoY
LTMMar 2026
-$90K-99.2% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+110.2%——
3-year CAGR-41.4%——
5-year CAGR——
10-year CAGR——

Debt Repayment history

USD · from the cash flow

Latest · FY2025
1.12M USD
Year-over-year change
+110.2%
4-year CAGR
-51.3%

Debt Repayment vs competitors

How CLNN compares with its peers on the latest reported figures

  • CLNN's LTM Mar 2026 debt repayment of $90K is the 3rd largest of the 11 companies compared; the peer median is $0.
  • Its year-over-year change of -99.2% is the 2nd highest of 3, against a peer median of -1613433.0%.
  • Debt repayment amounts to 67.2% of revenue for CLNN, versus a peer median of 0.0%.
CLNN Competitors Peer median
Debt Repayment for CLNN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PLRXPliant Therapeutics, Inc.LTM Mar 2026$32.27M -3226800.0%——
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$10.36M -66.1%——
CLNNClene Inc.LTM Mar 2026$90K -99.2%-41.4%67.2%
OVIDOvid Therapeutics Inc.LTM Mar 2026$0 ——0.0%
STTKShattuck Labs, Inc.LTM Mar 2026$0 ——0.0%
WHWKWhitehawk Therapeutics IncLTM Dec 2025$0 ——0.0%
MGNXMacroGenics, Inc.LTM Mar 2026$0 ——0.0%
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$0 ———
COYACoya Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
CNTBConnect Biopharma Holdings LimitedFY2025$0 ——0.0%
CNTXContext Therapeutics Inc.LTM Mar 2026$0 ———
Peer median (excluding CLNN) $0-1613433.0%—0.0%

Competitors are the stored peer set for CLNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(9.74M)(29.92M)(49.5M)(39.4M)(26.17M)
Depreciation & Amortization955K1.02M1.71M1.65M1.5M
Deferred Income Tax00000
Stock-Based Compensation12.38M8.51M9.12M7.95M6.38M
Change in Working Capital1M(1.54M)(191K)3.21M(3.35M)
Accounts Receivables(28K)(140K)46K79K64K
Inventory150K(2K)6K(31K)31K
Accounts Payables1.27M285K(1.51M)(264K)(348K)
Other Working Capital(386K)(1.68M)1.27M3.43M(3.1M)
Other Non-Cash Items(39.23M)(17.09M)8.7M5.27M3.1M
Operating Cash Flow(34.62M)(39.01M)(30.17M)(21.33M)(18.55M)
Capital Expenditures(1.33M)(5.18M)(330K)(15K)(39K)
Acquisitions (Net)00000
Purchases of Investments0(24.61M)(6.17M)(6.17M)0
Sales of Investments019.63M5M12.5M0
Other Investing Activities00000
Investing Cash Flow(1.33M)(10.16M)(1.5M)6.32M(39K)
Debt Repayment19.84M5.56M269K(10.9M)1.12M
Common Stock Issued9.25M11.46M42.09M9.24M10.4M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(1.98M)229K(200K)124K0
Financing Cash Flow27.11M17.25M42.16M(1.53M)11.52M
Effect of Forex Changes(85K)(30K)(4K)(127K)101K
Net Change in Cash(8.93M)(31.96M)10.49M(16.67M)(6.97M)
Free Cash Flow(35.96M)(44.19M)(30.5M)(21.34M)(18.59M)

Clene Inc.

NASDAQ:CLNN

Intrinsic Alpha fair value

Locked

Current Price

$3.66

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.